ACS Clinical Research Program
Atezolizumab in the adjuvant treatment of stage III colon cancer: Can PD-L1 inhibition improve survival?(0)
The study design for the ATOMIC trial (Alliance A021502), a randomized phase III study examining atezolizumab treatment of stage III colon cancer, is described.
Summarizes the results of the PRODIGE 7 trial, which compared the addition of hyperthermic intraperitoneal chemotherapy with contemporary perioperative systemic chemotherapy and cytoreduction.
Robotic surgery for hepatic neoplasms: Where does it fit in the minimally invasive surgery landscape?
This month’s column identifies prospective clinical trials aimed at clarifying the role of laparoscopic and robotic surgery for hepatic neoplasms.
New studies are identified suggesting that more frequent or intensive surveillance testing may not result in earlier detection of cancer recurrence.
Colorectal screening options for patients younger than 50 years of age and trends in colorectal cancer rates for this age group are summarized.
More in this category
- The evolving clinical management of sentinel node-positive melanoma: The impact of MSLT-II on clinical practice
- Liquid biopsies in cancer clinical trials
- Geriatric assessment and frailty in older cancer patients
- Immunotherapy in solid tumors
- Duration of adjuvant therapy for stage III colon cancer: No longer one size fits all
- Adjuvant therapies for biliary tract cancers
- Improving surgical care and outcomes through the OPTI-Surg toolkit
- Surgical management of ADH, ALH, and LCIS
- Clinical trials for surgeons: Hurdles and opportunities
- Present and future cancer staging with the eighth edition of the AJCC Cancer Staging Manual
- Induction chemotherapy and minimally invasive transanal surgery to increase organ preservation in rectal cancer
- Preventing colorectal adenomas in cancer survivors: An update on the PACES/S0820 trial
- ACS CRP sponsors educational sessions at Clinical Congress 2017
- Current role of immunotherapy in urologic cancers
- Gastrectomy for cancer: What are the benefits of a minimally invasive approach?